The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Multiple Myeloma
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294-3300
Local Institution - 0002, Phoenix, Arizona, United States, 85054
City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010
Local Institution - 0005, Jacksonville, Florida, United States, 32224
Northside Hospital, Atlanta, Georgia, United States, 30342
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, 02215
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Local Institution - 0001, Rochester, Minnesota, United States, 55905
Local Institution - 0010, Omaha, Nebraska, United States, 68198
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States, 07601
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2028-08-01